GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » 3-Year EPS without NRI Growth Rate

Kancera AB (OSTO:KAN) 3-Year EPS without NRI Growth Rate : 21.30% (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Kancera AB 3-Year EPS without NRI Growth Rate?

Kancera AB's EPS without NRI for the three months ended in Dec. 2024 was kr-0.08.

During the past 3 years, the average EPS without NRI Growth Rate was 21.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 32.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Kancera AB was 55.80% per year. The lowest was -45.70% per year. And the median was 18.70% per year.


Competitive Comparison of Kancera AB's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Kancera AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kancera AB's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kancera AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Kancera AB's 3-Year EPS without NRI Growth Rate falls into.


;
;

Kancera AB 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Kancera AB  (OSTO:KAN) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Kancera AB 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Kancera AB's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Kancera AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
N/A
Address
Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB Headlines

No Headlines